Tokgözoglu Lale, Zamorano José Luis
Hacettepe University, Ankara, Turkey.
University Hospital Ramon y Cajal, Madrid, Spain.
Drugs Context. 2020 Jun 12;9. doi: 10.7573/dic.2020-4-4. eCollection 2020.
A meeting entitled 'Current Perspective on the Use of Statins in the Treatment of Dyslipidemic Patients' was held in Stresa, Italy, on 27-28th June 2019. The presentations covered the 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines on dyslipidaemia, with discussion about the importance of controlling low-density lipoprotein cholesterol (LDL-C) and the pharmacological opportunities to reach the novel lipid goals. The roles of statins to manage dyslipidaemia in patients with different cardiovascular risks were also discussed. In particular, the efficacy and safety of pitavastatin for the treatment of dyslipidaemia were reviewed, highlighting its further advantages beyond LDL-C reduction. Therefore, the impact of statins on the glycaemic profile was discussed in view of the null/lower effect of pitavastatin as compared with other statins, as well as the interaction profile with other drugs commonly used. This meeting report summarizes the main messages of the discussion with a special focus on pitavastatin, whose main features in different settings are described.
一场名为“他汀类药物在血脂异常患者治疗中的应用现状”的会议于2019年6月27日至28日在意大利斯特雷萨举行。会议演讲涵盖了2019年欧洲心脏病学会（ESC）/欧洲动脉粥样硬化学会（EAS）血脂异常指南，讨论了控制低密度脂蛋白胆固醇（LDL-C）的重要性以及实现新的血脂目标的药物治疗机会。还讨论了他汀类药物在管理不同心血管风险患者血脂异常中的作用。特别是，回顾了匹伐他汀治疗血脂异常的疗效和安全性，强调了其除降低LDL-C之外的其他优势。因此，鉴于匹伐他汀与其他他汀类药物相比具有无效/较低的效应，以及与常用其他药物的相互作用情况，讨论了他汀类药物对血糖谱的影响。本会议报告总结了讨论的主要内容，特别关注匹伐他汀，并描述了其在不同情况下的主要特点。
